2 research outputs found
Bridgehead Alkene-Enabled Strain-Driven Bioorthogonal Reaction
Herein, we report a novel bioorthogonal reaction that
hinges on
a bridgehead alkene (BHA)-enabled inverse-electron-demand Diels–Alder
(IEDDA) cycloaddition. Readily accessible from natural product β-caryophyllene,
the strained BHA displays high reactivity toward the IEDDA reaction
while maintaining excellent biocompatibility. The developed IEDDA
reaction has been applied to in vitro protein labeling
and pretargeted live cell imaging
A Polymer-Based Antigen Carrier Activates Two Innate Immune Pathways for Adjuvant-Free Subunit Vaccines
The
activation of multiple Pattern Recognition Receptors
(PRRs)
has been demonstrated to trigger inflammatory responses and coordinate
the host’s adaptive immunity during pathogen infections. The
use of PRR agonists as vaccine adjuvants has been reported to synergistically
induce specific humoral and cellular immune responses. However, incorporating
multiple PRR agonists as adjuvants increases the complexity of vaccine
design and manufacturing. In this study, we discovered a polymer that
can activate both the Toll-like receptor (TLR) pathway and cyclic
GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway.
The polymer was then conjugated to protein antigens, creating an antigen
delivery system for subunit vaccines. Without additional adjuvants,
the antigen-polymer conjugates elicited strong antigen-specific humoral
and cellular immune responses. Furthermore, the antigen-polymer conjugates,
containing the Receptor Binding Domain (RBD) of the Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein or the Monkeypox
Antigen M1R as the antigens, were found to induce potent antigen-specific
antibodies, neutralizing antibodies, and cytotoxic T cells. Immunization
with M1R-polymer also resulted in effective protection in a lethal
challenge model. In conclusion, this vaccine delivery platform offers
an effective, safe, and simple strategy for inducing antigen-specific
immunity against infectious diseases
